Advances in Kinase Inhibitors to Highlight Day 1 at Inflammation in Drug Discovery & Development Meeting, June 24-25 Princeton, NJ
PRINCETON, N.J., March 27 /PRNewswire/ -- The world inflammatory disease research community will be convening in Princeton, NJ to attend, speak, and exhibit at ``Inflammation in Drug Discovery & Development,'' announces Strategic Research Institute. This conference will explore in detail -- research efforts to discover and develop safer and more effective therapies of rheumatoid arthritis and other inflammatory diseases & programs intended to generate next generation anti-inflammatory drugs.
The conference is organized into 4 main sections: 1) Novel Anti-TNF Proteins, 2) Advances in Small Molecule Anti-TNF Inhibitors, 3)IL-1 Receptors & Receptor Antagonists & 4) Additional Approaches for Novel Anti-Inflammatory Drugs. Featured topics on program include TNF blockers, BAFF, TACE Inhibitors, IRAK, p38 Kinase Inhibitors, Kineret, JNK Inhibitors, ICE, Traps, IKK, IL-2 Receptor Antibody, NFkB Pathway, etc.
Participants include: Abbott Laboratories, Amgen, Biogen, Celgene, Immunex, Merck Research Labs, National Institutes of Health, Nereus Pharmaceuticals Pharmacia Corporation, Pfizer Global R & D -- Groton Labs, Protein Design Labs, Regeneron Pharmaceuticals, Roche Bioscience Johnson & Johnson PRI, Scios Inc., Temple University, Vertex Pharmaceuticals, & Wyeth Research II.
To request the agenda, please contact Ed Drilon at edrilon@srinstitute.com or 212-967-0095 x233. Include your fax number, affiliation and mailing address.
To register for the exposition or inquire about sponsorship opportunities to augment your company's on-site exposure to prospective clients and collaborators (totebags, coffee mugs, luncheons, reception), please contact Mark Alexay at malexay@srinstitute.com.
SOURCE: Strategic Research Institute |
